FIELD: medicine.
SUBSTANCE: invention refers to gynaecology and oncology, and can be used for differential diagnosis of benign and malignant ovarian formations. Quantitative assessment is carried out in points of malignancy risk by formula AxBxC. A - features of the woman's age: reproductive age - 1 point, postmenopause - 4 points. B - presence of such ultrasonic signs as multi-chamber formation, solid formation, bilateral defeat, presence of ascites, presence of metastases. If observing no ultrasound sign B is equal to 1 point. If observing from two to five signs B is equal to 4 points. C is concentration of tumour marker HE-4 (pmol/l) in blood serum. Index value more than 170 in patients of reproductive age and more than 340 in postmenopausal women enables to predict malignant nature of ovarian formations.
EFFECT: method provides differential diagnosis of benign and malignant ovarian formations by using ultrasound findings and use as a tumour marker in blood serum HE-4.
1 cl, 3 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF ASCITIC-INFILTRATIVE OVARIAN CANCER AND ABDOMINAL TUBERCULOSIS | 2015 |
|
RU2585959C1 |
METHOD OF DIAGNOSING STAGES I-II OF HIGH-GRADE SEROUS OVARIAN CANCER USING THE LIPID PROFILE OF BLOOD SERUM | 2022 |
|
RU2807396C1 |
METHOD FOR PREDICTION OF OVARIAN CANCER PERITONEAL PROPAGATION | 2019 |
|
RU2722654C1 |
METHOD FOR PREDICTING THE POTENTIAL MALIGNITY OF OVARIAN TUMOR IN WOMEN OF REPRODUCTIVE AGE | 2019 |
|
RU2713795C1 |
METHOD OF DETERMINING RISK OF RECURRENCE OF ENDOMETRIOID OVARIAN CYSTS AFTER SURGICAL TREATMENT | 2023 |
|
RU2811890C1 |
METHOD FOR DETERMINING THE EFFECTIVENESS OF CHEMOTHERAPY WITH PLATINUM PREPARATIONS IN III-IV STAGE OVARIAN CANCER | 2020 |
|
RU2738167C1 |
METHOD FOR EARLY DIAGNOSTICS OF SEROUS OVARIAN CARCINOMA OF HIGH MALIGNANCY DEGREE BASED ON CHANGE CELLULAR COMPOSITION OF FALLOPIAN TUBE EPITHELIUM | 2016 |
|
RU2641094C1 |
METHOD FOR PREDICTION OF CYTOREDUCTIVE SURGERY VOLUME IN PATIENTS WITH ADVANCED OVARIAN CANCER AFTER COMPLETION OF THIRD COURSE OF NEOADJUVANT CHEMOTHERAPY | 2017 |
|
RU2671409C2 |
MINIMALLY INVASIVE METHOD FOR DIAGNOSIS OF HIGH-GRADE SEROUS OVARIAN ADENOCARCINOMA BASED ON COPY INDEX OF SULT1E1, CYP1B1, AND ESR1 GENES | 2021 |
|
RU2750472C1 |
Authors
Dates
2019-04-24—Published
2018-05-08—Filed